Clinical trial of shengjing capsule's efficacy on oligoasthernospermia

Lianming Zhao,Hui Jiang,Juqiao He,Yong Zhao,Lihu Wang,Anfang Zhou,Jihong Liang
DOI: https://doi.org/10.3969/j.issn.1008-0848.2017.02.008
2017-01-01
Abstract:Objective To investigate the clinical effects of shengjing capsules on oligoasthenospermia. Methods This clinical trial was a multicenter, open, dose-fixed and self-controlled study. The patients received Sheng Jing capsules 3 times a day, 4 capsules each time, for 3 months. Results Total of 265 patients finished this study, and their Average age was 32.7±5.32 years old ( 23 to 42 years old). Of the patients, 164 patients were Oligozoospermia, and 65.8% of them return to normal sperm concentration. The average sperm concentration increased from (19.47±15.7)×106/mL to (29.45±19.62)×106/mL for all patients. 253 patients had symptom of asthenozoospermia, and 49.4% of them returned to normal sperm comcentration. Only a patient suffered from stomach discomfort, a patient suffered from internal heat symptoms, without therapy, alleviated voluntarily. Conclusion Shengjing capsules were effective in treatment of oligoasthernospermia.
What problem does this paper attempt to address?